Skip to main content
SpringerLink
Log in

Antiarrhythmic Drugs 2013: State of the Art

  • Invasive Electrophysiology and Pacing (J Singh, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Antiarrhythmic drugs are widely used, but are of modest efficacy and have important side effects. However, even with the advance of catheter ablation for atrial fibrillation and ventricular tachycardia, antiarrhythmic drugs remain an important tool for treating arrhythmias. Antiarrhythmic drug development has remained slow despite much effort given our limited understanding of what role various ionic currents play in arrhythmogenesis and how they are modified by arrhythmias. This review will focus on promising new antiarrhythmic drugs undergoing clinical investigation or currently approved for clinical use, including amiodarone analogues, agents with novel ionic targets, and new drug combinations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • LafAuente-Lafuente C, Longas-Tejero MA, Bergmann JF, et al. Cochrane review 2012 antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5:CD005049. Excellent review of current clinically available antiarrhythmic drugs and their limitations.

    Google Scholar 

  2. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.

    Google Scholar 

  3. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.

    Article  PubMed  Google Scholar 

  4. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77.

    Article  PubMed  CAS  Google Scholar 

  5. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–99.

    Article  PubMed  CAS  Google Scholar 

  6. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety ofdronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597–605.

    Article  PubMed  Google Scholar 

  7. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–78.

    Article  PubMed  CAS  Google Scholar 

  8. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.

    Article  PubMed  Google Scholar 

  9. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268–76.

    Article  PubMed  CAS  Google Scholar 

  10. Morey TE, Seubert CN, Raatkainen MJP, et al. Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther. 2000;297:260–6.

    Google Scholar 

  11. Arya A, Silberbauer J, Teichman SL, et al. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009;11:458–64.

    Article  PubMed  Google Scholar 

  12. Ezekowitz MD, Nagarakanti R, Lubinski A, et al. A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012;34:1–9.

    Article  PubMed  Google Scholar 

  13. Gautier P, Guillemare E, Djandjighian L, et al. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004;44:244–57.

    Article  PubMed  CAS  Google Scholar 

  14. Gojkovic O, Aliot EM, Capucci A, et al. Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverterdefibrillator interventions. Hear Rhythm. 2012;9:217–24.

    Article  Google Scholar 

  15. Kowey PR, Crijns HJGM, Aliot EM, et al. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE Study. Circulation. 2011;124:2649–60.

    Article  PubMed  CAS  Google Scholar 

  16. Khitri AR, Aliot EM, Capucci A, et al. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. J Cardiovasc Electrophysiol. 2012;23:462–47.

    Article  PubMed  Google Scholar 

  17. Wettwer E, Hala O, Christ T, et al. Role of IKur in controlling action potential shape and contractility in the human atrium. Influence of chronic atrial fibrillation. Circulation. 2004;110:2299–306.

    Article  PubMed  Google Scholar 

  18. Voigt N et al. Left to right atrial inward-rectifier potassium current gradients in patient was paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:472–80.

    Article  PubMed  Google Scholar 

  19. Burashnikov A, Pourrier M, Gibson JK, et al. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol. 2012;5(2):400–8.

    Article  PubMed  CAS  Google Scholar 

  20. Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant: pharmacology electrophysiology, safety and efficacy. Drugs Today (Barc). 2008;44:325–9.

    Article  CAS  Google Scholar 

  21. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518–25.

    Article  PubMed  CAS  Google Scholar 

  22. Roy D, Pratt C, Juul-Moller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial [abstract]. J Am Coll Cardiol. 2006;47:10A.

    Google Scholar 

  23. Kowey PR, Roy D, Pratt CM, et al. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery. Circulation. 2007:114.

  24. Wettwer E, Christ T, Endig S, et al. The new antiarrhythmic drug Vernakalant: ex-vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovasc Res. 2013;98(1):145–54.

    Article  PubMed  CAS  Google Scholar 

  25. Lynch Jr JJ, Regan CP, Beatch GN, et al. Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues. J Cardiovasc Pharmacol. 2013;61(3):226–32.

    Article  PubMed  CAS  Google Scholar 

  26. Cheng JWM, Rybak I. Pharmacotherapy options in atrial fibrillation: focus on vernakalant. Clin Med Therapeutics. 2009;1:215–30.

    CAS  Google Scholar 

  27. Torp-Pedersen C, Raev DH, Dickinson G, et al. A randomized, placebo-controlled study of vernakalant (Oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol. 2011;4:637–43.

    Article  PubMed  CAS  Google Scholar 

  28. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775–83.

    Article  PubMed  CAS  Google Scholar 

  29. Bunch TJ, Mahapatra S, Murdock DK, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600–6.

    Article  PubMed  Google Scholar 

  30. Murdock DK, Kaliebe JW, Overton N. Ranolazine-induced suppression of ventricular tachycardia in a patient with non-ischemic cardiomyopathy: a case report. Pacing Clin Electrophysiol. 2008;31:765–8.

    Article  PubMed  Google Scholar 

  31. Kaliebe JW, Murdock DK. Suppression of non-sustained ventricular tachycardia with ranolazine: a case report. WMJ. 2009;108:373–5.

    PubMed  Google Scholar 

  32. Nanda S, Levin V, Martinez MW, et al. Ranolazine—treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy. Pacing Clin Electrophysiol. 2010;33:e119–120.

    Article  PubMed  Google Scholar 

  33. Murdock DK, Kaliebe JW. Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: a case report. Indian Pacing Electrophysiol J. 2011;11:84–8.

    PubMed  Google Scholar 

  34. Tagarakis GI, Aidonidis I, Daskalopoulou SS, et al. Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery. Curr Vasc Pharmacol. 2012 Nov 7. [Epub ahead of print].

  35. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011;108:673–6.

    Article  PubMed  CAS  Google Scholar 

  36. Murdock DK, Kersten M, Kaliebe J, et al. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9:260–7.

    PubMed  Google Scholar 

  37. Murdock DK, Kaliebe J, Larrain G. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series. Pacing Clin Electrophysiol. 2012;35:302–7.

    Article  PubMed  Google Scholar 

  38. Murdock DK, Overton N, Kersten M, et al. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8:175–81.

    PubMed  Google Scholar 

  39. Burashnikov A, Antzelevitch C. Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther. 2013;27:79–89.

    Article  PubMed  CAS  Google Scholar 

  40. Fredj S, Sampson KJ, Liu H, et al. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148:16–24.

    Article  PubMed  CAS  Google Scholar 

  41. Beyder A, Strege PR, Reyes S, et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel NaV1.5: a novel mechanism of drug action. Circulation. 2012;125:2698–706.

    Article  PubMed  CAS  Google Scholar 

  42. Parikh A, Mantravadi R, Kozhevnikov D, et al. Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. Hear Rhythm. 2012;9:953–60.

    Article  Google Scholar 

  43. Page RL, Connolly SJ, Wilkinson WE, et al. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. Am Heart J. 2002;143:643–9.

    Article  PubMed  CAS  Google Scholar 

  44. Page RL, Tilsch TW, Connolly SJ, et al. Asymptomatic or “silent” atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141–5.

    Article  PubMed  Google Scholar 

  45. Lombardi F, Borggrefe M, Ruzyllo W, et al. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-cardiOversion MaintEnance Trial-II) trial. Eur Heart J. 2006;27:2224–31.

    Article  PubMed  CAS  Google Scholar 

  46. Kerr CR, Connolly SJ, Kowey P, et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol. 2006;98:215–8.

    Article  PubMed  CAS  Google Scholar 

  47. Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation. 2004;110:3646–54.

    Article  PubMed  CAS  Google Scholar 

  48. Conway E, Musco S, Kowey PR. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol. 2008;102(suppl):12H–9H.

    Article  PubMed  CAS  Google Scholar 

  49. Dorian P, Al-Khalidi HR, Hohnloser SH, et al. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. J Am Coll Cardiol. 2008;52:1076–83.

    Article  PubMed  CAS  Google Scholar 

  50. Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiologic effects and safety. Drug Saf. 2008;31:95–107.

    Article  PubMed  CAS  Google Scholar 

  51. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.

    Article  PubMed  CAS  Google Scholar 

  52. Borer JS, Bohm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J. 2012;33:2813–20.

    Article  PubMed  CAS  Google Scholar 

  53. Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivavradine in patients with inappropriate sinus tachycardia. J Am Coll Cardiol. 2012;60:1323–9.

    Article  PubMed  CAS  Google Scholar 

  54. McDonald C, Frith J, Newton. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13:427–30.

    Article  PubMed  Google Scholar 

  55. Sutton R, Salukhe T. Ivabradine in the treatment of orthostatic intolerance. Europace. 2011;13:306–7.

    Article  PubMed  Google Scholar 

  56. Bohora S, Lokhandwala Y, Parekh P, et al. Reveral fo tachycardiomyopathy due to left atrial tachycardia by ivabradine. J Cardiovasc Electrophysiol. 2011;22:340–2.

    Article  PubMed  Google Scholar 

  57. • Burashnikov A, Sicouri S, Di Diego JM, et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216–24. First study to demonstrate synergistic effects between ranolazine and dronedarone in vitro.

    Article  PubMed  CAS  Google Scholar 

  58. Verrier RL, Pagotto VPF, Kanas AF, et al. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Hear Rhythm. 2013;10:121–7.

    Article  Google Scholar 

  59. Fragakis N, Koskinas KC, Katritsis DG, et al. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012;110:673–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Kapil Kumar and Peter J. Zimetbaum declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Harvard Vanguard Medical Associates, 133 Brookline Avenue, Boston, MA, 02215, USA

    Kapil Kumar

  2. Division of Cardiology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Baker 4, Boston, MA, 02115, USA

    Peter J. Zimetbaum

Authors
  1. Kapil Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Zimetbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Zimetbaum.

Additional information

This article is part of the Topical Collection on Invasive Electrophysiology and Pacing

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, K., Zimetbaum, P.J. Antiarrhythmic Drugs 2013: State of the Art. Curr Cardiol Rep 15, 410 (2013). https://doi.org/10.1007/s11886-013-0410-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-013-0410-2

Keywords

Search

Navigation